Novo Nordisk A/S
NOVO-B
주식 순위
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
주가
$39.74
시가총액
$175.38B
변동 (1일)
1.28%
변동 (1년)
-25.58%
국가
DK
거래 Novo Nordisk A/S (NOVO-B)
카테고리
Healthcare
Novo Nordisk A/S (NOVO-B)의 매출
Dec 2025 기준 매출 TTM: $48.55B
Novo Nordisk A/S의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $48.55B입니다. 2024년에 회사는 $40.52B의 수익을 올렸으며 이는 2023년의 $34.39B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Novo Nordisk A/S의 수익 기록 (2001 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $48.55B | 0.00% |
| 2025 | $48.55B | 19.82% |
| 2024 | $40.52B | 17.82% |
| 2023 | $34.39B | 35.02% |
| 2022 | $25.47B | 18.29% |
| 2021 | $21.53B | 3.33% |
| 2020 | $20.84B | 13.79% |
| 2019 | $18.31B | 6.63% |
| 2018 | $17.17B | -4.59% |
| 2017 | $18.00B | 13.46% |
| 2016 | $15.86B | 0.88% |
| 2015 | $15.73B | 8.89% |
| 2014 | $14.44B | -6.28% |
| 2013 | $15.41B | 11.69% |
| 2012 | $13.80B | 19.42% |
| 2011 | $11.55B | 6.01% |
| 2010 | $10.90B | 10.52% |
| 2009 | $9.86B | 15.53% |
| 2008 | $8.54B | 3.65% |
| 2007 | $8.24B | 20.44% |
| 2006 | $6.84B | 28.15% |
| 2005 | $5.34B | -0.14% |
| 2004 | $5.34B | 18.51% |
| 2003 | $4.51B | 27.01% |
| 2002 | $3.55B | 25.45% |
| 2001 | $2.83B | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $79.67B | 64.10% |
US
|
|
| $99.34B | 104.61% |
US
|
|
| $64.39B | 32.62% |
US
|
|
| $66.40B | 36.77% |
US
|
|
| $77.52B | 59.67% |
CH
|
